Lantheus Holdings, a company focusing on radiopharmaceuticals, is considering a possible sale after receiving a takeover offer from Curium Pharma, a private equity firm, valued at approximately $7 billion, according to a Friday report from Bloomberg News.
The two businesses have been in talks about a possible merger that might happen in a few weeks. According to the article, no final decision has been made, and there is no assurance that the discussions will lead to a deal.
During extended trading, the company’s shares, which have a market capitalization of roughly $6.15 billion, were down almost 2%.
Curium was valued at almost $7 billion when its owner, CapVest Partners, raised money for the nuclear medicine company’s continuing vehicle last year.
Due in part to demand for its cancer imaging agent, Lantheus’ first-quarter adjusted profit earlier this month exceeded analysts’ forecasts.
During the results call, interim CEO Mary Heino stated, “2026 is a year of commercial execution and regulatory milestones.”
“We’re making deliberate choices about where we focus our commercial efforts and deploying capital, so we’re positioned to deliver solid results in 2026 and accelerate growth in 2027.”
However, according to a William Blair analyst, Lantheus reaffirmed its annual profitability prediction while acknowledging that an upward revision is overdue but won’t happen until a permanent CEO is hired.
To give extra time to evaluate manufacturing-related data, the U.S. FDA extended its review of Lantheus’ diagnostic imaging kit, LNTH-2501, by three months in March.
By June 29th, the ruling is now anticipated.
A new formulation of the company’s prostate cancer imaging agent, Pylarify, was licensed by the regulator separately in March to increase scanning access through higher production capacity.
